Does dexmedetomidine influence opioid requirements among non-surgical critically ill children?

Background Mechanically ventilated, critically ill children require a multitude of potent sedative-analgesic medications in the pediatric intensive care unit (PICU). We aimed to evaluate whether early dexmedetomidine administration in the first 24 h of PICU admission was associated with reduced opioid administration among critically ill children. Methods This is a single center, observational cohort study of non-surgical, mechanically ventilated, critically ill children receiving sedative-analgesic medications in a quaternary PICU over a 12-year period. The cohort was divided into those who received dexmedetomidine for > 1 h within the first 24 h continuing through 72 h of admission and those who did not receive dexmedetomidine during the first 72 h. Weighted linear regression following propensity-score subclassification was used to evaluate the association between dexmedetomidine administration and mean opioid exposure during the subsequent 48 h. Results Among 26,954 PICU encounters, 662 (2.5%) met inclusion criteria and 122 (18%) received dexmedetomidine within 24 h of admission. Age and race did not differ between groups; patients receiving dexmedetomidine were more often female, had primary respiratory diagnoses, and had lower illness severity. Rates of early hypotension and bradycardia were similar between groups. In the multiple linear regression model, early dexmedetomidine was not associated with reduced 48-hour opioid requirements, while younger age and higher early opioid exposure were associated with increased opioid use. Propensity score subclassification achieved optimal covariate balance. Across treatment-only and multivariable weighted models, early dexmedetomidine was not significantly associated with decreased 48-hour opioid exposure. Early opioid exposure and perinatal diagnosis were associated with greater opioid administration. Conclusions Early dexmedetomidine initiation was not associated with reduced 48-hour opioid exposure. Further prospective, randomized trials are needed to clarify its role within sedative–analgesic regimens for critically ill children.